News
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best oversold NASDAQ stocks to buy now. On June 30, H.C. Wainwright ...
9h
HealthDay on MSNCertain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist TreatmentFor adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs), according to a study published online July 9 in ...
People who use GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, or GERD, a new ...
Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) ...
Men were three times more likely than women to say GLP-1s boosted their confidence and two times more likely to say they were going on more dates. They also reported higher libido, more matches and ...
New Phase II data presented at ENDO 2025 highlight avexitide’s potential to significantly reduce severe hypoglycemic events ...
11h
Sportschosun on MSNGastric and Jebbound ingredients, reducing dementia risk and mortality...Nervecerebrovascular protec...Recently, research results have been announced that GLP-1 (glucagon-like peptide) receptor agonist drugs have a positive ...
5h
News-Medical.Net on MSNGut-brain axis in eating disorders offers new treatment potentialUnderstanding the gut-brain axis is key to addressing eating disorders. This study highlights microbiota's influence and ...
Why confectionery giants are investing in snacks - from health pressures to shifting consumer habits, the future of food is ...
Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...
For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...
Mercer, a business of Marsh McLennan (NYSE: MMC) and a global leader in helping clients realize their investment objectives, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results